Christopher Sprando

Christopher Sprando practices at AHN Grove City Hospital in Grove City, Pennsylvania, part of Highmark Health.

Christopher Sprando's NPI, 1700892684, was assigned on July 31, 2006. Christopher Sprando graduated from University of Pittsburgh School of Medicine in 2003. Christopher Sprando holds Pennsylvania license MD427068.

Christopher Sprando's primary practice is AHN Grove City Hospital, at 631 North Broad Street Ext., Grove City, PA 16127 in Mercer County. The practice phone is (724) 450-7000.

Christopher Sprando's primary practice is AHN Grove City Hospital in Grove City, Pennsylvania, part of Highmark Health. Christopher Sprando is also affiliated with Allegheny General Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links Christopher Sprando to 2 more hospitals, 4 group practices and clinics, 3 medical groups and 2 home health agencies, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Sprando practices, 10 sites in all. Vendor and product names are available with a free account.

Family medicine is Christopher Sprando's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Christopher Sprando is licensed in Pennsylvania.

CMS data shows 855 Medicare services from Christopher Sprando across 14 procedure codes in 2024, for 344 Medicare patients. Medicare paid $72,032 for them.

CMS counts 344 Medicare patients who saw Christopher Sprando in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.21, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Christopher Sprando's median patient age at 70, with 53% women.

In 2024, Christopher Sprando wrote 20,106 Medicare Part D claims for 1,327 patients. 86% of them were for generic drugs. CMS names the drug for 19,189 of them, across 208 drugs with 11 or more claims each, at $1,665,400 in total drug cost. In 2023, CMS named 15,452 claims across 192 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Christopher Sprando for performance year 2024, reported through an alternative payment model (APM). Christopher Sprando accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Christopher Sprando as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 224 general payments to Christopher Sprando from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Novo Nordisk Inc paid the most, $1,805.

Christopher Sprando graduated from University of Pittsburgh School of Medicine in 2003.